Torcetrapid and atorvastatin - Should marketing drive the research agenda?

被引：22

作者：

Avorn, J ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 352卷 / 25期

关键词：

D O I：

10.1056/NEJMp058075

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2573 / 2576

页数：4

共 5 条

[1]

Avorn J., 2004, Powerful Medicines. The Benefits, Risks

[2] Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion [J].

Brousseau, ME ;

Diffenderfer, MR ;

Millar, JS ;

Nartsupha, C ;

Asztalos, BF ;

Welty, FK ;

Wolfe, ML ;

Rudling, M ;

Björkhem, I ;

Angelin, B ;

Mancuso, JP ;

Digenio, AG ;

Rader, DJ ;

Schaefer, EJ .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) :1057-1064

[3] Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol [J].

Brousseau, ME ;

Schaefer, EJ ;

Wolfe, ML ;

Bloedon, LT ;

Digenio, AG ;

Clark, RW ;

Mancuso, JP ;

Rader, DJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1505-1515

[4]

Davidson M, 2005, J AM COLL CARDIOL, V45, p394A

[5] Economic implications of evidence-based prescribing for hypertension - Can better care cost less? [J].

Fischer, MA ;

Avorn, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (15) :1850-1856

← 1 →